Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.51 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.50 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1623678 | 0.88 | RAD52 (0.55) | RAD52CXCR4GNAO1SIGMAR1CYP1A2 | |
| Piperazine SCHEMBL27980932 | 0.86 | RAD52 (0.53) | RAD52CXCR4GNAO1SIGMAR1CYP1A2 | |
| SCHEMBL11181437 | 0.86 | RAD52 (0.52) | RAD52CXCR4GNAO1SIGMAR1CYP1A2 | |
| SCHEMBL7122133 | 0.85 | GNAO1 (0.54) | RAD52CXCR4GNAO1 | |
| SCHEMBL9824369 | 0.85 | GNAO1 (0.54) | RAD52CXCR4GNAO1 | |
| SCHEMBL5467402 | 0.84 | CYP1A2 (0.48) | SIGMAR1CYP1A2CHRM5 | |
| SCHEMBL30115019 | 0.84 | HRH3 (0.54) | SIGMAR1CYP1A2CHRM5 | |
| SCHEMBL30115021 | 0.84 | HRH3 (0.54) | SIGMAR1CYP1A2CHRM5 | |
| SCHEMBL26067156 | 0.83 | GNAO1 (0.43) | GNAO1SIGMAR1 | |
| SCHEMBL24319448 | 0.83 | GNAO1 (0.53) | RAD52CXCR4GNAO1SIGMAR1CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2640712-B1 | 2-PIPERAZIN-1-YL-4H-1,3-BENZOTHIAZIN-4-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF MAMMALIAN INFECTIONS | ECOLE POLYTECHNIQUE FED LAUSANNE EPFL (CH) | 2018-07-11 | — | — | EP | disclosed |
| CN-107011287-A | The ketone derivatives of 2 piperazine, 1 base 4H, 1,3 benzothiazines 4 and its purposes for treating mammalian infections | 洛桑联邦理工学院(EPFL) | 2017-08-04 | — | — | CN | disclosed |
| US-8796264-B2 | 2-piperazin-1-yl-4H-1,3-benzothiazin-4-one derivatives and their use for the treatment of mammalian infections | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2014-08-05 | — | — | US | disclosed |
| EP-2640712-A1 | 2-PIPERAZIN-1-YL-4H-1,3-BENZOTHIAZIN-4-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF MAMMALIAN INFECTIONS | Ecole Polytechnique Fédérale de Lausanne (EPFL) (CH) | 2013-09-25 | — | — | EP | disclosed |
| US-20130245007-A1 | 2-PIPERAZIN-1-YL-4H-1,3-BENZOTHIAZIN-4-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF MAMMALIAN INFECTIONS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2013-09-19 | — | — | US | disclosed |
| WO-2012066518-A1 | 2-PIPERAZIN-1-YL-4H-1,3-BENZOTHIAZIN-4-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF MAMMALIAN INFECTIONS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2012-05-24 | — | — | WO | disclosed |
| EP-1627871-B1 | CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-7449466-B2 | Cyclic aminophenyl sulfamate derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-20060189625-A1 | Cyclic aminophenyl sulfamate derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| EP-1627871-A1 | CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE | Teikoku Hormone Mfg. Co., Ltd. (JP) | 2006-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245007-A1 | 2-PIPERAZIN-1-YL-4H-1,3-BENZOTHIAZIN-4-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF MAMMALIAN INFECTIONS | BPGM, TBC1D5, TBC1D15 | RAD52 2749/4885CXCR4 1577/4885GNAO1 2647/4885 |
| US-20060189625-A1 | Cyclic aminophenyl sulfamate derivative | SHBG, STS, ARSA | RAD52 2852/4885CXCR4 3689/4885GNAO1 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.